Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panacea Biotec Limited (PANACEABIO.NS)
New Delhi, IN
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.70% | +4.62% | +16.18% | +35.33% | +23.76% | +15.23% | -9.44% | +261.63% | +8.14% | +308.25% | +10,933.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+14.4% ★ Q1'26: +25.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+35.8% ★ Q1'26: +125.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-4.6% Q1'26: -15.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-5.9% Q1'26: -3.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-4.9% ★ Q1'26: -2.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +6.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.08× Q1'26: 2.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2006 actual |
Mar 2007 actual |
Mar 2008 actual |
Mar 2009 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.42B
est: 5.51B (-1.6%)
|
8.42B
est: 8.55B (-1.5%)
|
8.41B
est: 8.83B (-4.8%)
|
7.88B
est: 8.96B (-12.0%)
|
9.01B
est: 8.81B (+2.2%)
|
11.68B
est: 11.04B (+5.8%)
|
7.10B
est: 7.16B (-0.9%)
|
6.08B
est: 6.71B (-9.3%)
|
5.10B
est: 6.38B (-20.0%)
|
| EBITDA |
1.31B
est: 1.54B (-14.4%)
|
2.67B
est: 2.34B (+14.2%)
|
2.49B
est: 2.42B (+3.1%)
|
245.48M
est: 2.22B (-89.0%)
|
2.20B
est: -853.50M (+358.0%)
|
2.99B
est: 2.69B (+11.5%)
|
-774.80M
est: 1.29B (-160.3%)
|
-840.60M
est: -2.73B (+69.2%)
|
1.10B
est: -2.45B (+145.0%)
|
| EBIT |
1.13B
est: 1.22B (-7.4%)
|
2.29B
est: 1.85B (+23.7%)
|
2.03B
est: 2.03B (-0.1%)
|
-516.70M
est: 1.71B (-130.2%)
|
1.55B
est: -254.73M (+710.1%)
|
2.22B
est: 792.64M (+180.3%)
|
-1.55B
est: 1.10B (-240.0%)
|
-1.70B
est: -1.20B (-41.3%)
|
336.30M
est: 1.42B (-76.3%)
|
| Net Income |
592.47M
est: 654.51M (-9.5%)
|
1.48B
est: 1.25B (+18.1%)
|
1.29B
est: 1.52B (-15.4%)
|
-659.92M
est: 1.31B (-150.4%)
|
724.20M
est: -649.13M (+211.6%)
|
1.45B
est: 1.02B (+41.4%)
|
-2.06B
est: 939.12M (-319.0%)
|
-2.34B
est: -1.96B (-19.8%)
|
-1.12B
est: -2.23B (+49.7%)
|
| SGA |
3.45B
est: 1.34B (+156.6%)
|
4.63B
est: 1.99B (+132.9%)
|
482.79M
est: 1.23B (-60.9%)
|
458.23M
est: 1.49B (-69.3%)
|
474.66M
est: 1.57B (-69.8%)
|
1.33B
est: 2.17B (-38.9%)
|
1.46B
est: 1.28B (+14.2%)
|
909.40M
est: 3.38B (-73.1%)
|
759.40M
est: 2.22B (-65.8%)
|
| EPS |
9.57
est: 10.71 (-10.7%)
|
23.84
est: 20.57 (+15.9%)
|
19.51
est: 19.24 (+1.4%)
|
-9.82
est: -0.77 (-1,183.7%)
|
12.24
est: 10.76 (+13.7%)
|
22.98
est: 17.93 (+28.2%)
|
-33.58
est: -8.77 (-282.8%)
|
-38.25
est: -5.06 (-656.1%)
|
-18.31
est: -2.98 (-515.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-02 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajesh Jain | Chairman of the Board & MD | 10M | — |
| Sandeep Jain | Joint MD & Executive Director | 9M | male |
| Harshet Jain | Whole - Time Director | 8M | male |
| Ankesh Jain | Whole - Time Director | 8M | male |
| Rajeeva Kumar Mangalum | Chief Operating Officer | — | — |
| Sanjay Trehan | Director Technical & Compliances and Whole -Time Director | — | — |
| Vinod Goel | Group CFO and Head of Legal & Corporate Governance | — | male |
| Gurinder Pal Singh | Senior Vice President of Sales | — | male |
| Khalid Al Syed | Chief Scientific Officer | — | — |
| Naveen Kumar Jain | Vice President of NPI & Project Management | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PANACEABIO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
